%0 Journal Article
%A Schumann, Katharina
%A Klespe, Kai Christian
%A Mauch, Cornelia
%A Loquai, Carmen
%A Schultheis, Ulrike
%A Börger, Sevil
%A Thiem, Alexander
%A Emmert, Steffen
%A Hoellwerth, Magdalena
%A Koelbinger, Peter
%A Nguyen, Van Anh
%A Wanner, Marina
%A Richtig, Erika
%A Peitsch, Wiebke K
%A Harth, Wolfgang
%A Zenderowski, Veronika
%A Braun, Andreas Dominik
%A Mengoni, Miriam
%A Dummer, Reinhard
%A Mangana, Johanna
%A Maul, Lara Valeska
%A Meis, Frank
%A Rappersberger, Klemens
%A Persa, Oana Diana
%A Biedermann, Tilo
%A Posch, Christian
%T Switching PD-1 to BRAF + MEK inhibition improves recurrence-free survival in patients receiving a second course of adjuvant melanoma therapy.
%J Journal of the European Academy of Dermatology and Venereology
%V nn
%@ 0926-9959
%C Oxford [u.a.]
%I Wiley-Blackwell
%M DKFZ-2025-00939
%P nn
%D 2025
%Z epub
%X PD-1 or BRAF + MEK inhibition is considered the current gold standard in adjuvant melanoma therapy. Little is known if, after the recurrence of the disease and surgery, a second course of adjuvant therapy might be beneficial.A multicenter, retrospective study investigating a second course of adjuvant therapy after recurrence and surgery in stage III-IV melanoma patients. Patients received nivolumab (NIV), pembrolizumab (PEM) or dabrafenib plus trametinib (D + T) between 01/2017 and 10/2021. The primary endpoint was 12-month recurrence-free survival (RFS2). Further analyses included descriptive and correlative statistics.Sixty-six patients from 22 centers in Germany, Austria and Switzerland were included. Thirty-two patients received D + T as second-course adjuvant therapy, 9 patients received PEM and 25 patients received NIV. Recurrence-free survival for the second-course adjuvant treatment (RFS2) was assessed after 12 and 24 months and showed a superiority of adjuvant BRAF + MEK over PD-1 therapy (12-months RFS2: 90.6
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:40331873
%R 10.1111/jdv.20708
%U https://inrepo02.dkfz.de/record/300825